Neumora Flags Going Concern Doubt as Cash Runs Short
NMRA sits 99% above its 52-week low of $0.83 on light trading volume (0.3× avg).
Summary
Neumora's 10-Q warns of substantial doubt about its ability to continue as a going concern, with cash insufficient to fund operations for twelve months. The company also amended its loan terms and raised $20.4M via ATM sales.
Key Events · Earnings and Guidance · NMRA
-
Going Concern Warning
The company states substantial doubt exists about its ability to continue as a going concern within one year, as $116.8M in cash will not fund operations for at least twelve months.
-
Loan Covenant Amendment
Third Amendment to K2 HealthVentures loan extends interest-only period to April 2029 but modifies minimum liquidity covenant to 50%, 110%, or waived depending on milestones/market cap; $445,000 amendment fee paid.
-
ATM Dilution Continues
Neumora raised $20.4M net proceeds through at-the-market sales in H1 2026 under its $300M ATM program with Leerink.
-
Debt Conversion
K2HV converted $2.05M of term loan principal into 2,336,448 shares at $0.8774 per share in February 2026.
Analysis · NMRA · Life Sciences
Neumora's Q2 10-Q discloses substantial doubt about its ability to continue as a going concern. With $116.8M in cash and a burn rate that will not fund operations for twelve months, the company must raise additional capital or face a liquidity crisis. The filing also reveals a Third Amendment to its K2 HealthVentures loan that extends the interest-only period to April 2029 but tightens liquidity covenants, and shows continued reliance on dilutive ATM sales ($20.4M raised in H1 2026). This is a critical survival signal for a clinical-stage biotech that just discontinued its lead depression drug.
At the time of this filing, NMRA was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $320.5M. The 52-week trading range was $0.83 to $3.65. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.